Cullinan Therapeutics, Inc. (CGEM) Stock
5 of the hedge funds AlphaScala tracks reported CGEM in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $7.24M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own CGEM?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 397K | $7.24M | +57% |
| Millennium Management Israel Englander | 346K | $6.30M | -0% |
| Renaissance Technologies Jim Simons (founder) | 327K | $5.95M | +1% |
| Point72 Steve Cohen | 75K | $1.37M | -92% |
| Marshall Wace | 66K | $1.20M | -94% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Cullinan Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 8, 26 | Michaelson Jennifer | Chief Scientific Officer | SELL | 8.0K | $173K |
| Aug 13, 26 | Michaelson Jennifer | Chief Scientific Officer | SELL | 30.0K | $608K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →CGEM price chart
Powered by TradingViewWhat does Cullinan Therapeutics, Inc. do?
Cullinan Therapeutics Inc. is an early-stage biopharmaceutical company focused on developing targeted therapies for cancer treatment. The company specializes in a range of innovative approaches including immuno-oncology and precision medicine. Its pipeline encompasses a variety of programs targeting defined mutations and tumor-specific mechanisms, aiming to deliver highly effective therapies with fewer side effects compared to traditional treatments. Cullinan Therapeutics Inc. operates within the biotechnology and healthcare sectors, playing a crucial role in advancing cancer treatment options through its novel and strategic drug development processes. By employing a diversified portfolio of therapeutic assets early in their development, the company seeks to address unmet medical needs across multiple cancer indications. This approach not only exemplifies Cullinan's commitment to innovation but also increases its significance in the market as a contributor to the expanding field of targeted cancer therapies.